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Intake of energy as well as interest in palatable foods diminish during the ageing 
process. One of the likely reasons underlying this phenomenon is an age-related 
decrease in the opioid tone in the brain. To further substantiate this hypothesis, 
the current project was aimed to elucidate the effects of an opioid receptor 
antagonist, naltrexone, on energy- and palatability-driven consumption in 6-, 16- 
and 22-month old mice and on the activation of feeding-related forebrain 
circuitry (hypothalamic and accumbal) in adult vs old male mice. The findings 
indicate that old (22-month old) mice exhibit diminished responsiveness to 
anorexigenic properties of naltrexone in deprivation-induced intake of “bland” 
chow and eating for reward (consumption of low-/non-calorie solutions 
containing sucrose and saccharin). Interestingly, in the pilot studies performed in 
rats, sensitivity to anorexigenic action of naltrexone was similar at two different 
phases of adult lifespan prior to reaching the old age (2 months and 18months). 
The c-Fos immunoreactivity analysis in mice indicated that unlike in adult animals 
at a younger age, in old animals, naltrexone fails to activate the nucleus 
accumbens shell, the ventromedial and hypothalamic nuclei, and it activates the 
lateral hypothalamus. These c-Fos data provide an insight into neural 
responsiveness changes that might underscore differential feeding regulatory 
outcomes seen after naltrexone administration in old animals compared to their 
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1. Introduction – Literature review 
1.1. Homeostatic regulation of food intake: 
Mechanisms which govern food intake are conserved throughout the animal 
kingdom, including in humans. Food is consumed for a number of reasons, the 
main one being to replenish lacking energy. This is the primary drive underlying 
our motivation to eat. Eating helps us to meet our energy demands and maintain 
homeostasis.  
Feeding activity consists of three key components. The first is the initiation 
phase; this is when the energy needs of the organism in combination with 
external factors, such as availability of food, palatability of food and social 
interactions, to name a few, facilitate a search for food. The second phase, the 
procurement, is when an animal seeks out the food through intense foraging and 
finally the third one is the actual consumption. As eating continues the 
mechanisms which drive satiation and termination of a meal gradually ensue (1). 
During these stages of food intake both peripheral and central mechanisms are 
“interacting” with each other to keep the body within homeostasis to prevent 
both starvation and extreme overeating. The brain coordinates with the 
periphery to control the intake of food. This control is due to changes in energy 
levels which arise in the periphery and signal back to the brain (2). These 
mechanisms can be short- (e.g., neuropeptide Y release upon presentation of a 
food cue) and long-term (e.g. leptin release from the adipose tissue) in order to 
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initiate feeding during calorie depletion and terminate feeding at the time of 
satiety (3). 
Consumption for energy is controlled at the central nervous system (CNS) level 
by a complex network of brain sites that are interconnected by intricate 
molecular mechanisms. The majority of these sites are localised within two key 
anatomical subregions of the central nervous system (CNS), the brain stem and 
the hypothalamus. Both the hypothalamus and the brain stem are capable of 
receiving neurohormonal and nutrient-derived signals arising in the periphery. 
The brain stem also “communicates” with the peripheral organs via a direct 
afferent-efferent vagal neural pathway (4). 
Several decades of research have led to the identification of discrete 
hypothalamic and brainstem sites that play a particularly critical role in the 
control of eating for energy. Already in 1981, Leibowtz et al. found that lesioning 
the paraventricular nucleus of the hypothalamus in rodents promotes extreme 
overeating and eventually leads to obesity (5). Knife cut experiments determined 
that severing connections between the brain stem and the PVN greatly hampers 
the ability of the animal to develop satiation and it prolongs a meal (6). 
Furthermore, since the PVN sends the projections to the pituitary as well as to 
multiple CNS targets, developmental abnormalities pertaining to this area result 
in aberrant feeding behaviour (7). In this context, the SIM-1 gene mutation, 
which underlies improper neuropeptidergic cytoarchitecture of the PVN, is 
associated with obesity in mice (8, 9). The impaired satiety response in animals 
with a PVN dysfunction does not come as a surprise considering that PVN 
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neurons typically exhibit an increased level of activity upon meal termination 
(10). Thus, anomalous neuronal network development at the PVN level serves as 
a neuropathology underlying a vast and abnormal processing of feeding-related 
signalling throughout the brain stem-hypothalamic pathways (and beyond). 
While the initial research on central regulation of appetite focused on the PVN, 
mounting evidence pointed to additional hypothalamic sites as co-players 
involved in this process. The current literature signifies the importance of the 
brainstem hypothalamic network that encompasses in the hypothalamus the 
PVN, SON, DMH, VMH, ARC and LH in the hypothalamus (11). 
 
Figure 1: Schematic representation of the brainstem-hypothalamic network involved in 
homeostatic regulation of food intake (i.e., hunger-reward; blue colour). Reward pathways that 
control consumption for pleasure are depicted in yellow. Details related to the functioning of 
the two circuits are described in the text. 
 
Each of these sites contributes to shaping the final outcome of the 
orexigenic/anorexigenic responses observed under specific circumstances, yet it 
is clear that the combined activity of the entire feeding-related central network 
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plays a decisive role in generating a dynamic change in appetite induced by 
transient and long-term environmental and physiological challenges. For 
example, the supraoptic nucleus (SON) contains oxytocin and vasopressin (12) 
neurons, which are activated upon excessive stomach distension and increase in 
plasma osmolality (those parameters accompany meal termination). (13, 14). 
DMH ablation in rats leads to hypophagia and reduces body weight (15) DMH-
lesioned rats do not show sensitivity to anorexigenic properties of an opioid 
receptor antagonist, naloxone, which is known to diminish feeding induced by 
pleasant taste (16). On the other hand, while ablation of the VMH causes 
hyperphagia (17), the general neuronal activity of this site in rats is dependent on 
these animals’ body weight (18). Several populations of LH neurons, including 
those that synthesise orexin A and melanin concentrating hormone, promote 
consumption, (19) however, it should be noted that their influence on food 
intake (especially in the case of orexin cells) is closely tied with the regulation of 
sleep-wake (and locomotor activity) cycle (20). 
Finally, the arcuate nucleus (ARC) plays a special role in this network of 
hypothalamic sites as is crucial in how the peripheral and central signals which 
regulate food intake are integrated (21). The ability of the ARC to be responsive 
to peripheral signals stems from the weak blood-brain barrier in this area. Hence, 
hormones, such as leptin or cholecystokinin, are able to directly affect ARC 
neurons containing relevant receptors (22). The neurons within the ARC are 
stimulated by a large range of hormones and changes in nutrients. It is thought 
to act as a conveyor of information from all these different signals involved in 
homeostasis to other areas of the brain (23). 
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It should be noted that this brainstem-hypothalamic network of sites is able to 
receive peripheral information associated with the feeding/energy status of the 
animal. This ability of this circuitry to respond to peripheral signals stems from, 
among others, the fact that some hormones released by the GI tract, adipose 
tissue, liver and pancreas can penetrate through the blood-brain barrier and 
induce a change in neuronal activation (24). In addition, some of those 
peripheral signals – even though they are not BBB-penetrant – are able to reach 
their receptors in the brain in those central areas where the BBB is very weak 
(for example, the ARC and – in the brain stem - the dorsal vagal complex, 
especially the AP) (25). 
From this point of view, significant research effort has been dedicated to the 
understanding the feeding effects arising from the functional link between GI 
hormones such as ghrelin, PYY, and insulin, and the CNS. One of the key 
hormones which relay information about the body’s metabolic stores is ghrelin 
(26). An orexigenic hormone, ghrelin, is secreted by the stomach during energy 
deprivation and – particularly in an abundant manner – before a scheduled meal 
(27). When ghrelin is peripherally injected into Siberian hamsters they increase 
all behaviours shown in there feeding repertoire such as, foraging, intake and 
hoarding (28). Other studies show that when a ghrelin receptor antagonist is 
injected, food intake is decreased in lean mice, mice with an obesity inducing 
diet (high fat & high sugar) and in ob/ob knockout obese mice (29). Importantly, 
ghrelin signals to the brain via receptors located in the brain stem and the 
hypothalamic arcuate nucleus, but the communication within the larger network 
leads to the integration of the signal within pathways that converge at the 
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hypothalamus (30). Other key hormones include peptide YY (PYY) also from the 
GI tract, this has the opposite effect of ghrelin and many studies have shown the 
peripheral administration of PYY in rats and mice not only decreases food intake 
and weight gain (including in deprivation-induced intake) but also increases 
neuronal activity (measured by c-Fos immunoreactivity) in the arcuate nucleus 
(31, 32). In human studies, PPY infusion decreases food intake in healthy and 
obese subjects (33). Pancreatic hormone, insulin, is released after a spike in 
glucose levels during refeeding, but it also works to stop glucose levels getting 
too low during fasting by releasing glucose stores from the liver (1). In rodent 
studies, central injections of insulin decrease intake of both chow (34). When 
rats are chronically injected with insulin they show a suppression of food intake 
paired with weight loss and this change is returned to normal after infusions 
cease (35).  
Importantly, the CNS sites that regulate food intake utilize a number of 
molecules as a means of synaptic transmission between neurons belonging to 
this vast network. The hypothalamic network of sites mentioned above utilises a 
vast array of neuropeptides and neurotransmitters to execute the host of proper 
neuroendocrine and behavioural responses to energy balance/feeding-related 
challenges. Orexigenic molecules include NPY, Agouti-related protein, melanin 
concentrating hormone and orexin; whereas oxytocin, corticotropin releasing 
hormone, CART and vasopressin serve as anorexigens. These molecules are 
dispersed throughout the hypothalamus allowing for the flow of neutrally 
mediated information to occur. For example, at the “entry level” into the CNS, 
adipocyte hormone leptin stimulates the release of anorexigenic peptides by 
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activating pro-opiomelanocortin (POMC) and cocaine and amphetamine related 
transcript (CART) when energy levels have been adequately met and also works 
to inhibit the release of orexigenic peptides neuropeptide-Y (NPY) and agouti-
related peptide (AgRP) (26). During times of energy insufficiency ghrelin 
stimulates both NPY and AgRP and these peptides work to inhibit the stimulation 
of the anorexigenic peptides (36). Orexigenic peptides such as NPY act to 
increase food intake and the intake of calories where as anorexigenic peptides 
such as melanocortins have an opposite effect where they work to decrease food 
intake and body weight (37). Arcuate POMC neurons (one splice product of 
POMC is an anorexigenic melanocortin ligand, alpha-melanocyte stimulating 
hormone) stimulated by leptin send projections to the hypothalamic PVN, where 
they terminate on anorexigenic oxytocin, vasopressin and CRH cells, leading to 
an increase in the activity of this hypophagic network (38, 39), On the other 
hand, orexigenic beta-endorphin (another POMC splice product) release from 
ARC terminals at the PVN level, stimulated by ghrelin’s action, leads to a 
decrease in oxytocin signalling arising from the PVN, likely hampering meal-
suppressing activation of PVN OT neuronal population.  
Furthermore, activity of the aforementioned hypothalamic network of sites is 
also regulated by input from the brain stem. This is important from the point of 
food intake regulation as the brain stem receives vagal afferents which carry 
information directly from the gut. The nucleus of the solitary tract (NTS) and 
dorsal motor nucleus of the vagus, the two brainstem nuclei directly involved in 
this process (1), send projections to forebrain areas (1), thereby affecting not 
merely a drive to eat (or the need to discontinue consumption), but also 
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memory, motivation and motor patterns that ensure having energy 
requirements adequately met (40). 
 
Figure 2: The central metabolic circuitry is regulated by numerous endocrine and neural inputs. 
Schematic illustration of how brain networks regulating ingestive behaviour communicate with 
peripheral organs. Hormones supplying information about the peripheral metabolic state to 
the brain include the gastrointestinal peptides ghrelin and PYY(3-36), insulin from the pancreas 
and leptin from adipose tissue. Ghrelin and leptin act both on the hypothalamus (Arc) and the 
brainstem (nTS). The afferent portion of the vagus nerve innervates most of the 
gastrointestinal tract where it collects information about the immediate alimentary state, and 
terminates in the nTS. The lipid mediator OEA is produced in the duodenum and activates the 
brainstem, possibly via the vagus nerve. Both the Arc (via antagonistic NPY- and POMC-
expressing cells) and the nTS project further into the brain in parallel pathways to engage 
higher brain regions into ingestive behaviour. Outputs from the brain regulating energy 
expenditure include both branches of the autonomic nervous system; the sympathetic system 
whose preganglionic neurones are located in the intermediolateral cell column (IML), which is 
directly innervated by POMC neurones from the Arc, as well as the parasympathetic system 
with preganglionic neurones for the efferent portion of the vagus nerve located in the dorsal 
motor nucleus of the vagus (DMX). The efferent autonomic innervation regulates, e.g. glucose 
homeostasis via actions in liver and skeletal muscle. From Brain regulation of food intake and 




1.1.1. The reward system: 
Aside from eating for energy, there is another critical factor that propels animals 
to consume food. This factor is palatability. Typically, in humans and in animal 
models that are used to study food intake regulation, sweet and/or fatty foods 
are considered to be particularly attractive. Palatable foods are overeaten in no-
choice and choice paradigms. It has been well established that offering animals a 
high-sugar or high-fat diet as the only source of calories will lead to excessive 
consumption of such diet over standard chow (41, 42). Furthermore, if a 
palatable and bland diets are offered simultaneously, animals will mainly eat the 
palatable (thus, preferred) food (43, 44). Interestingly, in choice scenarios, 
consumption of the “bland” chow never really ceases even if the other diet 
option is highly palatable (adding to the multidimensionality of feeding reward 
that encompasses variety of food rather than only relative palatability as a 
singular factor) (45). When two palatable diets are given (for example, HF and 
HS), some animals show inherent preference for one of the tastes. (46, 47). It 
should be noted that solid foods are not always the only source of energy and/or 
flavour. Importantly, liquid diets/solutions/etc also serve as an important source 
of calories and thus should be considered as “food” (48). 
Palatability is just one of the factors which mediate reward, as intake can be 
stimulated by cognitive cues such as the smell or a visual image. Cognitive cues 
are enough to motivate consumption of the palatable tastant due to the 
orbitofrontal cortex processing (49). Overall, even a completely satiated 
(understood as energy-nondeprived) animals will continue to consume palatable 
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food in excessive amounts simply because its tastes pleasant. The reward 
component of food can be powerful enough to override our homeostatic 
systems in place and seek out foods whose consumption is not necessary to fulfil 
our energy needs or – in fact – foods that might potentially jeopardise our 
homeostasis because of, e.g., high salt content (50). 
 
Figure 3: Sensory factors that make food attractive may over-ride existing satiety signals. 
Schematic diagram to show how sensory factors interact in the orbitofrontal cortex with 
satiety signals to produce the hedonic, rewarding value of food, which leads to appetite and 
eating. Cognitive factors directly modulate this system in the brain. Figure from Taste, olfactory 
and food texture reward processing in the brain and the control of appetite (51). 
 
The question arises here as to what central mechanisms underlie this liking and 
wanting of palatable foods which motivate animals to eat in excess. The key 
component of the reward system is the ventral tegmental area-nucleus 
accumbens pathway, which is a part of the corticolimbic system (51). The 
presence of, anticipation and consumption of palatable food has been shown to 
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increase activation of neurons within this pathway (52, 53). Individuals that due 
to underlying mental health pathology, such as e.g. depression, are anhedonic, 
or that due to a temporary inability to process external stimuli (e.g., extreme 
stress), experience anhedonia, show a diminished activation of the NAcc to 
natural rewards, including food (54).   Lesions to the shell of the NAcc in rodents 
have been shown to impair the learning of how the reward source was located 
and received as they were unable to relocate the reward in a maze trial after the 
lesion (55). In VTA lesion studies, palatable sucrose solution consumption is 
significantly decreased, giving evidence to the VTAs role in reward and 
promoting intake of ingestants characterised by pleasant taste (56).The NAcc and 
VTA mediate the rewarding components of natural reinforcers such as food 
(especially high sugar and high fat diets), but also substances which can be 
abused such as drugs (57); consequently, these findings paved the way to 
concluding that intake of highly palatable foods has addictive-like properties 
(58). 
The molecular systems that underlie the activity of the reward pathways 
comprise of dopamine, GABA and opioids. Dopamine is synthesised in the VTA 
and released from VTA-derived projections into the NAcc. Importantly, this 
release is triggered by presentation of various rewards, most notably, food. The 
greater the attractiveness of the food, the more robust activation of this 
pathway occurs (59). In the presence of palatable food, there is a release of 
dopaminergic neurons in the NAcc and this release of dopamine is thought to 
increase future motivation to seek out this palatable food through increasing 
arousal, motor activities and a coordinated learning response to the substance 
12 
 
(26). Dopamine neurons primary function is to reinforce the behaviours which 
lead to the exposure of the rewarding substance and is associated with the 
learning and motor functions which are required for behaviour for motivation to 
seek out the food which is a positive reinforcer (2). The release of dopamine into 
the NAcc is triggered by foods and other rewards but also to their predictive cues 
when a reward is about to occur (60). Studies have shown that dopamine 
antagonist’s block the learning of behaviours that lead to the reward that 
dopamine helps to reinforce (61).  Geary and Smith in 1985, showed that sham-
fed sucrose intake in the rat is decreased when injected with dopamine 
antagonist, pimozide, by removing the positive reinforcing effect of this sweet 
drink (62).  
Early GABA studies have implicated its role in food intake and reward through 
increasing consumption. The ICV administration of a GABA receptor agonist 
increases food intake in already sated pigs and when paired simultaneously with 
the receptor antagonist this response is abolished (63). Furthermore when AgRP 
cells known to stimulate food intake in mice are deleted in mice and unable to 
release GABA, mice become lean and resistant to obesity (64). When GABA 
agonists are injected directly into the VTA   there is an increase in food intake 
(65). Furthering this evidence, a blockade of GABA receptors promotes weight 
loss in mice (66). 
Opioids and opioid antagonists also play a key role in influencing food intake for 
reward. Opioid receptors located in numerous brain sites, including the 
hypothalamic PVN, LH, ARC, VMH and DMH and the amygdala (including the 
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central and basolateral nuclei) and mediate palatable food intake (67). Many 
studies have implicated opioids and their role in taste preferences and thus 
reward.  Opioid antagonists such as naltrexone and naloxone (NLX) have long 
been shown to decrease the consumption of palatable substances (68). Levine et 
al, in 1995 gave evidence to the role opioids have in reward by measuring the 
effect of NLX on rats given access to either standard or sweetened chow. They 
found NLX to be more potent in those rats fed the sweetened chow as NLX 
blocked the rewarding aspect of the sweet taste (69). A blockade of the opioid 
receptors in the PVN and ACe using naltrexone also decreases both palatable and 
non-preferred food consumption (67). Administration of NLX decreased normal 
taste preferences in binge and control eaters and this decrease is more potent in 
sweet high fat foods considered highly palatable (70).Conversely, opioids drive 
the intake of preferred food choices such as high sugar and high fat (71). 
Importantly, all classes of opioids (dynorphins, endorphins and enkephalins) 
increase food intake in human and laboratory animal studies (72, 73).  
Homeostatic mechanisms and the reward system are intertwined in how they 
affect consumption. For example, ghrelin - mentioned above for its role in 
hunger signalling - is also involved in the reward system. It signals to the VTA 
during palatable meal consumption, so intake of the food is increased. This is due 
to ghrelin causing an increase in the number of dopamine neurons firing within 
the VTA (74). Glucagon-like peptide-1 and oxytocin injections in the nucleus 
accumbens decrease food intake. On the other hand, opioid peptides suppress 
satiety signalling derived from oxytocin neuronal activation even in 
circumstances under which potential food toxicity may endanger the internal 
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milieu (14). In essence, the mechanisms which drive palatable food intake have 
extremely high efficiency precisely because they do not require any hunger 
signals or actual energy needs to occur. Instead, any cue that drives us to seek 
out feeding reward may trigger consumption of energy. This means large 
amounts of food can be consumed even when the stomach is distended and 
nearly at full capacity, despite ensuing toxicity, hyperosmolality and general lack 
of energy needs (75). 
 
 
Figure 4: Schematic representation of neural circuits that regulate feeding. Dopaminergic 
neurons originating in the VTA project to neurons within the nucleus accumbens of the ventral 
striatum. The lateral hypothalamus receives input from GABAergic projections from the 
nucleus accumbens as well as melanocortinergic neurons from the Arc of the hypothalamus. In 
addition, melanocortin receptors are also found on neurons in the VTA and the nucleus 
accumbens. Figure from Homeostatic and hedonic signals interact in the regulation of food 
intake (76). 
 
1.1.2. Aging studies; human and animal studies: 
Aging has long been associated with a decrease in appetite. This phenomenon, 
also referred to as ‘anorexia of aging’, is poorly understood (76). At a very young 
age preferences for food are just beginning to form especially when a change in 
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the diet occurs during the gradual switch from an exclusive milk diet to an 
extremely varied diet available in a typical environment rich in foods and dietary 
choices (77). There is an innate preference for the taste of sweet and salty 
flavours and the rejection of foods that are sour and bitter, and this is combined 
with the capacity to learn and develop new preferences (78).  At an old age, 
disturbances in appetite occur. The most prevalent one is eating anhedonia, 
defined according to the DSM-IV (1994) as the loss of ability to feel pleasure that 
one would normally receive from preferable foods (79). Donini et al (2003) 
reported a decline in food intake and a lack of motivation to consume food in 
this older age (80). Although aging has been linked to a decline in food intake 
strictly for the purpose of energy consumption (due to decreased energy 
expenditure) (81), one should note that this decline arises from multiple other 
factors. One of the main issues is a decreased ability to perceive taste. Age has 
been found, for example, to be associated with decreased responsiveness to 
salty and sweet solutions (82). It stems from several reasons. One of them is 
poor oral health, which affects – among others – salivary output and contributes 
to poor initial phases of food digestion in the oral cavity, thereby diminishing 
availability of molecules capable of activating taste receptors (83). The other is 
the reduction in density of taste buds correlated with aging (84). There are 
changes in the olfactory system: for example, participants in a study aged from 
65- 80, over half showed olfactory deterioration, and this decline in the sense of 
smell progressed with age; 75% of participants who were 80 and over were 
affected by this decline (85). One study has suggested that reduced food 
consumption is caused by an increase in satiety signalling from the periphery 
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including an increase in the amount of circulating leptin, paired with a decline in 
motivation to seek and consume food (86).  Currently, virtually no studies exist 
which examine the effect that aging has on the brain in food intake-related sites. 
As the population is aging is important to look into the mechanisms which cause 
these appetite disturbances as we are still far from understanding. It is agreed 
among studies that there is a loss of appetite found consistently in humans aged 
over 65, but how this loss is mediated is currently unknown. This is where animal 
studies hold relevance. 
These differences in food intake have been analysed in several animal models 
such as work done by Frutus et al (2012) with young and old rats looking at the 
changes in the hedonic value of food that tends to occur with aging and the 
motivation to obtain this food (87). They found that old rats had a decreased 
motivation to get food as there was a significant decline in the amount of effort 
exerted on the incentive runway compared to the younger cohort of rats. The 
ability to develop associations has also been assessed by Renteria et al (2008) in 
rats at 24 months of age. They found that rats which were given both sweetened 
and unsweetened solutions showed no preference for either and consumed very 
similar amounts of both solutions even though the more palatable option should 
have shown a higher consumption (88). This effect of aging has also been shown 
in mice with both young and old cohorts (89). In this study it was found that the 
old mice consumed significantly less 1% sucrose solution and with the 5% 
sucrose solution which also involved a larger amount of effort and novel 
exploration the old mice again showed reduced consumption and effort. 
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Research has also shown that fasting in both young and old mice leads to an 
increase in the motivation to feed in the young cohort but not in the old, 
however the old mice showed higher levels of acyl ghrelin present which is 
known to stimulate food intake. Old mice injected with acyl ghrelin also showed 
no increase in food intake compared to young mice where feeding significantly 
increased (90). A similar study of old rodents deprived of chow for 72 hrs showed 
they were unable to gain back the weight lost from fasting or eat enough to 
cover the lost calories during the refeeding period (91).  
Importantly, the few studies that have been performed thus far suggest that 
aging animals show a diminished sensitivity to opioid receptor ligands in terms of 
the effectiveness of the injectants to change appetite. For example, mice aged 1-
2 months and 24-30 months were injected with either agonist ketocyclacine and 
morphine or the antagonist NLX. The young mice increased feeding when 
injected with the agonists and decreased intake after NLX. However, the old mice 
were insensitive to opioid receptor ligands (92). Similarly, Gosnell et al. found 
that 24-month old rats did not change food intake even after an injection of a 
high dose of an opioid receptor agonist, butorphanol, or an antagonist naloxone. 
To date, there have been no studies on the effectiveness of another opioid 
receptor antagonist, naltrexone in relation to aging and appetite (93). In light of 
these findings as well as of clear gaps in knowledge, continuation of studies 
exploring altered responsiveness of aging animals to both feeding reward as well 
as of drugs that affect feeding reward is essential. 
1.2. Overarching goals and specific aims:  
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The overarching goal of this project was to determine central mechanisms which 
underlie changes in food intake regulation at an old age. Specifically, the effect of 
an opioid receptor antagonist, naltrexone, on intake of tastants that differ in 
palatability and on the activation of feeding-related forebrain circuitry 
(hypothalamic and accumbal) was established. Animal models were employed in 
the studies. The project consisted of the following specific aims: 
1. Determine the minimum dose of naltrexone required to reduce the 
consumption of “bland” chow, and palatable sucrose and saccharin solutions in 
6-, 16- and 22-month old mice. 
2. Determine naltrexone-induced patterns of brain activity (defined by mapping 
c-Fos immunoreactivity) in feeding-related forebrain in the hypothalamus and 
accumbal complex (shell and core) sites in adult and old male mice. 
3. Determine the effects of naltrexone and butorphanol in adult rats that differ in 
age (2 and 18 months old). 
It should be noted that while the mouse study focused on determining the 
effects of age that approaches the end of a typical lifespan of a laboratory 
mouse, rat studies looked at animals considered to be “adult”, however, still a 
significant time away from reaching the final stages of life. Because of this 
discrepancy in age, in rats, both agonist and antagonist were used to 
substantiate the findings, whereas in the old mice, only the antagonist was 




2. Materials and Methods 
Animals: 
All experiments had prior approval of the Animal Ethics Committee at the 
University of Waikato. 6-month old, 16-month old and 22-month old C57BL male 
mice were placed into a single-housed environment in a standard macrolon cage. 
16, 2 month old and 19, 18 month old Sprague Dawley rats were also placed into 
a single housed environment in standard rat cages. The animal facility was 
temperature controlled at 22oC with a 12:12 hour light:dark cycle where the 
lights turn on at 0700. Food (Sharpes feed) and water were available ad libitum 
unless it has been otherwise stated. 
2.1.  Experiment 1: The effect of naltrexone on deprivation induced  
  chow intake in 6-, 16 -and 22-month old male mice. 
The 16-month old mice were placed into four treatment groups (n=8). The 6 
month old mice were placed into five treatment groups (n=10). The treatment 
groups for both 6- and 16-month old animals are: control (saline), 0.1, 0.3 and 
1.0 mg/kg of naltrexone. The 6-month old mice were injected with 3.0 mg/kg as 
the fifth treatment group.  The 22 month old mice were injected with saline, 1.0, 
3.0 or 10.0 mg/kg of naltrexone (n=9/group). Prior to injection, animals were 
deprived overnight of chow, water available ad libitum. On experimental day all 
animals were then injected intraperitoneally with saline or naltrexone at one of 
the varying doses. Post injection they were given access too regular chow, intake 
is measured for 1 h.  
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2.2. Experiment 2: The effect of naltrexone on sucrose intake in 6-, 
16- and 22-month old male mice. 
Six- and 16-month old mice were treated with saline (control), 0.1 and 0.3 mg/kg 
of naltrexone (6 m.o., n=10; 16 m.o., n=8 per group). The 22 month old mice 
received saline, 1.0, 3.0 or 10mg/kg of naltrexone (n=9/group). On the 
experimental day all animals were injected intraperitoneally with either saline or 
naltrexone at one of the varying doses as stated above. Just prior to the doses 
being administered, chow and water were removed.  Once injected, animals 
were given access to a 10% sucrose solution and consumption was measured 
after 2 h. 
2.3. Experiment 3: The effect of naltrexone on saccharin intake in 6-, 
16- and 22-month old male mice. 
Six- and 16-month old mice were treated with saline (control), 0.1, 0.3 and 1.0 
mg/kg of naltrexone (6 m.o., n=10; 16 m.o., n=8 per group). The 22 month old 
mice received saline, 1.0, 3.0 or 10mg/kg of naltrexone (n=9/group). On the 
experimental day all animals were injected intraperitoneally with either saline or 
naltrexone at one of the varying doses as. Just prior to the doses being 
administered, chow and water were removed.  Once injected, animals were 
given access to a 0.1% saccharin solution and consumption was measured after 1 
h. 
2.4. Experiment 4: The effect of naltrexone on neuronal activity in 6 
month old and 16 month old male mice. 
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Animals were split into two groups (n=5 (aged), n=6 (6 m.o.)), which were saline 
(control) and 1.0 mg/kg of naltrexone (treatment). On the experimental day, 
group 1 from each age cohort received an injection of saline and the group 2 
from each age received 1.0 mg/kg of naltrexone. Prior to the injection food and 
water were removed. After 60 minutes animals were euthanized (see description 
below). 
Euthanasia and Perfusions: 
Sixty minutes post-injection, the mice were deeply anaesthetised with 0.6 mL of 
35% urethane and were intracardially perfused with 50 mL of a 4% 
paraformaldehyde (PFA) solution in a 0.1 mol L-1 phosphate buffer with a pH of 
7.4. Once perfused their brains are dissected out and placed in the PFA solution 
for a further 48 hours in a refrigerator set at 4 degrees. 
Immunohistochemistry: 
The brains were postfixed in PFA for 48 hours and they were transferred to Tris-
buffered saline (TBS). A vibratome (Leica) was used to cut 60-μm coronal brain 
sections. Brain sections were treated for 10 minutes in a 3% H2O2 in 10% 
methanol (in TBS) solution, washed in TBS incubated at 4oC overnight with goat 
anti-rabbit anti-c-Fos antibody (1:15000; SYSY) in a supermix solution (0.25% 
gelatin and 0.5% Triton x-100 in TBS). Sections were washed again in TBS and 
incubated for one hour in anti-rabbit antibody in supermix (1:400; Vector 
Laboratories). After another set of washes with TBS, the sections are incubated 
for another hour in avidin-biotin complex (ABC) that is diluted also in supermix 
(1:800; Vector Laboratories). This all occurs at room temperature on an agitator. 
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After the final incubation in ABC the sections are rinsed again and placed in a 
0.05% diaminobenzidene (DAB) (Millipore), 0.01% H2O2 and 0.2% Nickel 
sulphate solution in TBS for 10 minutes allowing staining to develop.  
Mounting: 
The sections were mounted onto gelatinised microscope slides and left to dry. 
They were then dehydrated in increasing concentrations of ethanol (70%, 90%, 
100%) for 10 minutes at a time, immersed in xylene for 20 minutes, then cover 
slipped using Entallan (Merck, Switzerland). 
Analysis: 
The sections were examined using a light microscope and images were gathered 
using a camera (Olympus DP70) and analysed using the software imageJ. The 
areas of interest were located using the neuroanatomical atlas by Paxinos and 
Watson. The forebrain areas were analysed using imageJ to count the Fos-
positive nuclei bilaterally per brain site. Data were analysed by taking the 
number of active neurons per sq mm of tissue and then averaged per animal and 
per group. 
2.5. Experiment 5: The effect of naltrexone on deprivation-induced 
food intake in 2-month old and 18-month old rats 
The 2 month and 18 month old rats were injected with saline, 0.1, 0.3 and 1.0 
mg/kg of naltrexone (18 m.o., n=10, 2 m.o., n =8).  Animals were deprived 
overnight of chow, water still available ad libitum prior to injection. On the 
experimental day animals were injected intraperitoneally with either saline or 
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naltrexone at one of the varying doses. Once injected they were given access to 
regular chow, intake was measured at 1 h.  
2.6. Experiment 6: The effect of naltrexone on the intake of a 10% 
sucrose solution in 2- and 18-month old male rats. 
Two- and 18-month old rats were treated with saline (control), 0.1, 0.3 and 1.0 
mg/kg of naltrexone (2 m.o., n=10; 18 m.o., n=8 per group). On the experimental 
day all animals were injected intraperitoneally with either saline or naltrexone at 
one of the varying doses as stated above (Exp. 5). Just prior to the doses being 
administered, chow and water were removed.  Once injected, animals were 
given access to a 10% sucrose solution and consumption was measured at 1 h. 
 
2.7. Experiment 7: The effect of naltrexone on 0.1% saccharin intake 
in 2- and 18- month old male rats. 
Two- and 18-month old rats were treated with saline (control), 0.1, 0.3 and 1.0 
mg/kg of naltrexone (2 m.o., n=10; 18 m.o., n=8 per group). On the experimental 
day all animals were injected intraperitoneally with either saline or naltrexone at 
one of the varying doses as stated above (Exp. 5). Just prior to the doses being 
administered, chow and water were removed.  Once injected, animals were 
given access to a 0.1% saccharin solution and consumption was measured at 1 h. 
2.8. Experiment 8: The effect of butorphanol on ad libitum food 
intake consumption in 18 month old male rats. 
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18 month old rats are placed into three treatment groups (n=9) and injected with 
saline, 0.03 and 0.1 mg/kg of butorphanol.  Food is available ad libitum prior to 
and on the experimental day. On the experimental day all animals had their 
chow removed just prior to being injected intraperitoneally saline or butorphanol 
at one of the doses as stated in Exp. 8. Once injected, animals were re-given 
access too regular chow, and their food intake was measured over 4 hours. 
Statistics:  
Results are presented as means ± standard error (SEM). Data were analysed 
using one-way ANOVA followed by Fisher’s post-hoc test with the exception of 
two-group comparisons where the Student’s t-test was used.  Values were 








3.1. Experiment 1: Different doses of naltrexone are required to 
decrease deprivation-induced chow intake in 6- 16- and 22-
month old mice. 
Naltrexone significantly reduced deprivation-induced chow intake at 3.0 mg/kg 
in 6 month old mice (Figure 4).  In 16 month old mice, the 1.0 mg/kg dose of the 
drug was effective (Figure 6). Finally, in the 22 month old mice a dose as high as 







Figure 5: The effect of saline, 0.1, 0.3, 1.0 and 3.0 mg/kg of NTX on deprivation induced chow 
intake consumption in male 6 month old mice. NTX was injected IP following overnight 
deprivation of regular chow, food intake was then measured after an hour. The data is recorded 
































Figure 6: The effect of saline, 0.1, 0.3 and 1.0 mg/kg of NTX on deprivation induced chow intake 
consumption in male 16 month old mice. NTX was injected IP following overnight deprivation of 
regular chow, food intake was then measured after an hour. The data is recorded as mg of food 





Figure 7: The effect of saline, 1.0, 3.0 and 10 mg/kg of NLX on deprivation induced chow intake 
consumption in male 22 month old mice. NTX was injected IP following overnight deprivation of 
regular chow, food intake was then measured after an hour. The data is recorded as mg of food 
consumed per kg of body weight. * (p = <0.05) significantly different from saline. 
 
 
3.2. Experiment 2: Different doses of naltrexone are required to decrease 






















In 6- and 16-month old animals that were episodically exposed to the 10% 
sucrose solution, 0.3 mg/kg of naltrexone suppressed the 2-h consumption of the 
palatable tastant (Figures 8, 9). On the other hand, the oldest cohort of mice 
showed a decrease in sucrose intake only after a 10 mg/kg dose (Figure 10). 
  
Figure 8: The effect of saline (control), 0.1, 0.3mg/kg of NTX on sucrose intake in 6 month old 
male mice. NTX was injected IP with sucrose being presented immediately after. Sucrose intake 
was then measured. The data is recorded as ml of sucrose consumed per kg of body weight. * (p 




Figure 9: The effect of saline (control), 0.1, 0.3mg/kg of NTX on sucrose intake in 16 month 
male mice. NTX was injected IP with sucrose being presented immediately after. Sucrose intake 
was then measured. The data is recorded as ml of sucrose consumed per kg of body weight. * (p 












































Figure 10: The effect of saline (control), 0.1, 0.3 and 1.0 mg/kg of NTX on sucrose intake in 22 
month old male mice. NTX was injected IP with sucrose being presented immediately after. 
Sucrose intake was then measured. The data is recorded as ml of sucrose consumed per kg of 
body weight. * (p = <0.05), ** (p = <0.01) significantly different from saline. 
 
3.3. Experiment 3: Naltrexone has no effect on saccharin intake in 16- and 
22-month old mice, but it decreases consumption in the 
youngest cohort. 
Episodic saccharin intake was decreased by ca. 30% in 6 month old mice injected 
with 1.0mg/kg of naltrexone (Figure 11). The same dose of the drug had no 
effect in the older cohort of 16-month old mice (Figure 12). Even 10 mg/kg of the 



























Figure 11: The effect of saline (control), 0.1, 0.3 and 1.0 mg/kg of NTX on saccharin intake in 6 
month old male mice. NTX was injected IP with saccharin being presented immediately after. 
Saccharin intake was then measured after 1 hour. The data is recorded as ml of saccharin 
consumed per kg of body weight. 
 
 
Figure 12: The effect of saline (control), 0.1, 0.3 and 1.0 mg/kg of NTX on saccharin intake in 16 
month old male mice. NTX was injected IP with saccharin being presented immediately after. 
Saccharin intake was then measured after 1 hour. The data is recorded as ml of saccharin 
consumed per kg of body weight. 
 
 
Figure 13: The effect of saline (control), 1.0, 3.0 and 10.0 mg/kg of NTX on saccharin intake in 
22 month old male mice. NTX was injected IP with saccharin being presented 
immediately after. Saccharin intake was then measured after 1 hour. The data 
is recorded as ml of saccharin consumed per kg of body weight 
 
3.4. Experiment 4: Naltrexone activates a different subset of feeding-


























Among the seven hypothalamic areas analysed in this study, in the 
younger cohort, the VMH, DMH, ARC, PVN and SON show a significantly 
increased neuronal activation after the naltrexone treatment. In the older 
animals, the DMH, ARC and PVN exhibit higher Fos immunoreactivity, 
too, whereas the activation of the VMH and SON is unchanged in the 
naltrexone- vs saline-injected animals. On the other hand, significantly 
more LH neurons are Fos-positive in this cohort.   Among the two reward-
related sites, the nucleus accumbens shell is activated by naltrexone in 
the younger group, but the activation is the same in the older animals. 







Figure 14: The effect of Saline and 1.0 mg/kg of NTX on neuronal activity in specific brain sites 
in 6 and 16 month old male mice. NTX was injected IP, after one hour mice were perfused with 
brains extracted for C-Fos activity. The data is recorded as the number of Fos positive neurons 




Figure15: Photomicrographs depicting c-Fos immunoreactivity within the paraventricular 
nucleus (PVN) of the hypothalamus of 6 and 16 month old male mice injected with saline or 
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naltrexone. (A), Saline and 6 m.o. mice (B), NTX and 6 m.o. mice (C) Saline and 16 m.o. mice, and 
(D) NTX and 16 m.o. mice. 
 
 3.5. Experiment 5: Naltrexone reduces deprivation-induced chow 
intake in 2 and 18 month old rats. 
The two month old rats had a significant decline in deprivation induced intake at 
0.3mg/kg  of naltrexone (Figure 16) The same dose of the drug was required in 
18 month old rats (Figure 17). 
 
Figure 16: The effect of saline, 0.1, 0.3 and 1.0 mg/kg of NTX on deprivation induced food 
intake consumption in 2 month old rats. NTX was injected IP following overnight deprivation of 
regular chow, food intake was then measured. The data is recorded as mg of food consumed per 
kg of body weight. * (p = <0.05), ** (p= <0.01) significantly different from saline. 
 
 
Figure 17: The effect of saline, 0.1, 0.3 and 1.0 mg/kg of NTX on deprivation induced food intake 













































food intake was then measured. The data is recorded as mg of food consumed per kg of body weight. * (p = 
<0.05), ** (p= <0.01) significantly different from saline. 
 
3.5. Experiment 5: Naltrexone reduces sucrose intake in all age 
groups 
A dose of 0.3mg/kg of naltrexone is needed to significantly reduce sucrose intake 
in 2 month old rats (Figure 18). A similar result is seen in the 18 month old rats as 
0.3mg/kg of naltrexone is required also (Figure 19). 
  
Figure 18: The effect of saline (control), 0.1, 0.3 and 1.0 mg/kg of NTX on sucrose intake in 2 
month old male rats. NTX was injected IP with sucrose being presented immediately after. 
Sucrose intake was then measured. The data is recorded as ml of sucrose consumed per kg of 
body weight. * (p = <0.05), ** (p= <0.01), *** (p = <0.001) significantly different from saline. 
 
Figure 19: The effect of saline (control), 0.1, 0.3 and 1.0 mg/kg of NTX on sucrose intake in 18 











































* *** ** 
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Sucrose intake was then measured. The data is recorded as ml of sucrose consumed per kg of 
body weight. * (p = <0.05), ** (p= <0.01) significantly different from saline. 
 
3.6. Experiment 6: Naltrexone does not reduce consumption of 
saccharin in either age group. 
Saccharin seems to be non-preferred in our Sprague Dawley strain of rats. 
Naltrexone administered at 1.0 mg/kg shows no significant suppression in 2- and 
18- month old rats (Figures 20, 21). 
 
 
Figure 20: The effect of saline (control), 0.1, 0.3 and 1.0 mg/kg of NTX on saccharin intake in 2 
month male rats. NTX was injected IP with saccharin being presented immediately after. 















































Figure 21: The effect of saline (control), 0.1, 0.3 and 1.0 mg/kg of NTX on saccharin intake in 18 
month old male rats. NTX was injected IP with saccharin being presented immediately after. 
Saccharin intake was then measured after 1, 2 and 4 hours. The data is recorded as ml of 
saccharin consumed per kg of body weight. 
 
3.7. Experiment 7: Butorphanol increases the consumption of ad 
libitum chow intake in 18 month old rats 
 





Figure 22: The effect of saline (control), 0.03 and 0.1 butorphanol on ad libitum chow intake in 
18 month old male rats. Butorphanol was injected IP with regular chow being present ad libitum. 
Intake was then measured at 1, 2 and 4 hours. The data is recorded as mg of chow consumed per 



























































As individuals age and reach the final stages of their lifespan, their risk of 
developing disturbances in food intake increase. One of the most typically seen 
problems is age-related anorexia in which individuals do not ingest sufficient 
amount of food to maintain their energy stores (94). This gradually leads to a 
decline in body weight, widely reported for humans and laboratory animal 
species (80,95). The second problem is associated with a decreased interest in 
palatable tastants (96). In this context, even when foods that are (and have 
earlier been) considered as highly attractive, are presented at an old age, they do 
not appear to convey the same motivating and rewarding value as during the 
earlier life stages (97). 
The issue of a decreased motivational value of palatable foods at an old age is 
evident in the very few animal model studies available thus far, which have 
consistently shown that old rats and mice consume smaller amounts of palatable 
solid foods and palatable solutions in choice and no-choice scenarios (87). To 
further support the notion of diminished sensitivity to food-driven reward at an 
old age, initial experiments suggested that laboratory rodents injected with 
opioid receptor ligands display a shift in their responsiveness to orexigenic or 
anorexigenic properties of select doses of such compounds (93). 
The current set of studies involving mouse and rat models confirms the 
previously reported phenomenon of diminished consumption of food at an older 
age. My experiments show that at an old age, mice display a diminished 
sensitivity to anorexigenic properties of an opioid receptor antagonist, 
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naltrexone; whereas adult rats that have not yet reached the age that would 
mirror a more advanced life stage (≤18 months), do not differ in their sensitivity 
to the drug. The c-Fos studies define a differential pattern of neuronal activation 
after naltrexone injection at a younger versus older age as a possible underlying 
reason for the changed feeding response at an older age to the same dose of the 
drug. 
A decreased drive to obtain food associated with advanced age is confirmed by 
the outcome of the experiments presented in this thesis. Although not formally 
compared in the course of the study, it is evident that in all paradigms used 
herein, intakes of palatable tastants and “bland” chow were lower in more age-
advanced cohorts of animals. For example, in mice, in deprivation-induced chow 
intake, the 22-month old mice eat on approximately 10g less of chow per kg/b. 
wt. compared to 6 month old mice. In sucrose-presented animals the 22 moth 
old consume approximately 40g less of sucrose per kg/ b. wt. compared to 6 
month old mice. In the saccharin paradigm 18 month old mice consumed 40g 
less of saccharin per kg/b. wt. compared to 6 month old mice. This trend 
indicating a decrease in consumption is apparent even in two adult cohorts of 
rats – the 2-month old rats eat on average 40g of chow per kg/b. wt. and 70g of 
sucrose per kg of b. wt., whereas 18-month old rats eat 13g and 30g, 
respectively. 
As suggested by previously done research, the current studies involving 
naltrexone injections in mice show that while the younger animals (6- and 16-
months old) require 0.3-3 mg/kg b. wt. naltrexone to decrease any aspect of 
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food intake (palatability- and energy-driven), 22-month old mice need as much 
as 10 mg/kg b. wt. naltrexone to show hypophagia. In fact, in the saccharin 
experiment, even a 10-mg/kg dose was ineffective in the 22-month old group.  
On the one hand, the data confirm the effect of opioid ligand administration in 
adult (not yet old) animals. In those studies, antagonists, such as naltrexone, 
typically cause a reduction in deprivation-induced chow intake at doses (in the 
case of naltrexone and naloxone) around 0.3-3 mg/kg b. wt., whereas 
consumption of palatable ingestants in such animals is generally suppressed by 
somewhat lower doses (0.1 mg/kg is oftentimes sufficient). This is in line with the 
concept of opioids affecting primarily the aspect of feeding driven by pleasure 
and – only to some extent – the component driven by energy needs (98). 
Conversely, opioid receptor agonists increase consumption of palatable foods 
and fluids more avidly than of “bland” tastants. For example, a mu opioid 
receptor agonist DAMGO injected directly into the Nacc, a key site of reward, 
increases intake of saccharin (99). An opiate, morphine, is particularly effective in 
increasing consumption of preferred tastants, but it also elevates intake of 
regular chow in sated animals (100). Kappa opioid receptor agonist, dynorphin A, 
also increases consumption of palatable tastants and it elevates operant 
responding for palatable sugar pellets (101). In line with that, the expression of 
kappa and mu opioid receptor changes upon exposure to palatability as well as 
energy deprivation (102, 71). 
As opioid agonists and antagonists show differential effects on aging animals, it is 
crucial to note there is little information on why these differential effects occur 
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and the effect that aging has on neuronal activity in feeding-related sites. This 
gap in in knowledge had led me to ask the question as to whether animals at an 
old age differ from younger adult cohorts in the magnitude of anorexigenic 
responses to an opioid receptor antagonist naltrexone and whether feeding-
related hypothalamic and accumbal areas display a different responsiveness to 
opioid antagonism in animals at an adult versus more advanced age. To begin 
this project, a naltrexone dose response curve to deprivation-induced chow 
intake, and sucrose and saccharin consumption without deprivation, was 
established in aging cohorts of mice. A lower dose of naltrexone (0.3mg/kg) is 
required to reduce deprivation-induced chow intake in 6- and 16-month old 
mice. The 22 month old mice were insensitive to lower doses; they required 10.0 
mg/kg of naltrexone to cause a significant response. In line with these current 
results were the data obtained by Gosnell et al who studied the effects of 
naloxone in aging Fisher rats. Naloxone in the 2- and 12-month old rats 
supressed intake at all doses (0.1, 1.0 and 10.0mg/kg), whereas the rats aged 22 
and 28 months were insensitive to naloxone’s effects at all doses (93). Another 
study confirmed the suppressive effects of naltrexone in Syrian hamsters under 
the deprivation-induced feeding paradigm with decreased food intake and body 
weight (103).  
In the episodic sucrose intake paradigm in mice in the current set of 
experiments, the same lower dose of 0.3mg/kg was required to decrease 
consumption in 6-and 16-month old animals. The 22-month old mice were 
insensitive to the effects of naltrexone at lower doses. This is an insensitivity not 
seen in the younger age groups. Many studies confirm the suppressive effect of 
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naltrexone on sucrose consumption. For example, Beczkowska et al in 1992, in a 
similar paradigm to this current study, found that naltrexone administration 
decreased sucrose consumption in a dose dependant manner in rodents (104). In 
rhesus monkeys, behaviour maintained by access to sucrose as a reward is 
reduced by central injections of naltrexone (105). Although there is abundant 
evidence of the suppressive effects of naltrexone on sucrose intake in many 
different experimental scenarios, studies on the effects of aging on sucrose-
motivated eating behaviour remain limited. 
 The next step in the experimental phase was to establish the effect of 
naltrexone on 0.1% saccharin intake. Six-month old mice showed a decrease in 
consumption of saccharin at a lower dose (1.0 mg/kg). At 16 and 22 months old, 
the mice drank very little saccharin and naltrexone failed to suppress this further. 
Many studies have been able to reliably reduce saccharin intake following opioid 
antagonist administration. Beczkowska et al showed significant decreases of 
saccharin consumption following an ICV injection of naltrexone in rats (106). 
Conversely a study using an opioid receptor agonist DAMGO found an increase in 
saccharin intake (99).  
There is little data on age-driven differences in brain circuitry’s responsiveness to 
foods or eating-related cues in humans. One of the few fMRI studies published 
thus far reported that taste-derived activity of secondary and higher order taste 
processing and reward regions such as the orbitofrontal cortex, amygdala, 
hippocampus, thalamus, and caudate nucleus occurs in both older and younger 
individuals, but – surprisingly – additional brain areas are activated in the older 
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cohort (107). In another fMRI study in older adults with the metabolic syndrome, 
differences in the hypothalamic activity were noted upon sweet taste sensory 
stimulation (108). Animal data support the notion of differential brain 
responsiveness to food-related cues. For example, Kotz et al. showed that Fos 
immunoreactivity response to central injection of an orexigenic peptide, orexin 
A, is diminished in aged rats (109). Age-induced alterations in brain distribution 
of critical neural modulators of appetite, such as nitric oxide, dynorphin, and 
NPY, have also been observed (110). 
Numerous studies have shown usability of c-Fos immunoreactivity mapping in 
defining the CNS sites of action of specific drugs as well as in defining brain areas 
associated with particular behavioural and physiological phenomena, including 
food consumption. Previous experiments have pointed that opioid receptor 
antagonists, such as naloxone and naltrexone, induce activation of specific 
neuronal populations that are involved in, among other phenomena, appetite 
control. For example, in animals subjected to a scheduled access to palatable 
food, naltrexone increases Fos immunoreactivity in the VTA, NAC shell, and 
central nucleus of the amygdala as well as the bed nucleus of the stria terminalis. 
In food restricted adult rats, naltrexone induced Fos expression in the LH, DMH 
and ARC (111). Finally, in sated rats, central naltrexone infusion elevates Fos in 
the LH (112). In line with those findings, morphine withdrawal increases Fos 
immunoreactivity in the PVN (113). Another opioid receptor antagonist, 
naloxone, causes an increase in c-Fos expression in the ARC of lactating dams. 
Funabashi et al reported that naloxone has a stimulatory effect on Fos 
expression in the mediobasal hypothalamus (114). Finally, pretreatment with 
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naloxone blocks the pheromone-induced changes in Fos patterns in the PVN 
(115). 
Considering a differential responsiveness of the brain circuitry in aged vs younger 
individuals to food-related cues (both actual food-related sensory stimuli as well 
as molecules that promote changes in appetite, such as orexin), it is not 
surprising that in the current c-Fos experiments utilising naltrexone, a somewhat 
different set of brain sites was activated by the very same dose of the antagonist 
in each of the two groups.  Differences were noted in the VMH and the SON, 
these two sites being activated in the 6-month old mice.  Conversely, the LH was 
activated only in the older cohort. At the same time, while there was a clear 
difference in how the three aforementioned brain sites responded to naltrexone, 
there was a “core” of hypothalamic areas which exhibited elevated c-Fos 
immunoreactivity regardless of the animals’ age. Those included the PVN, ARC, 
DMH and CeA.  These sites may remain unchanged in response to naltrexone due 
to the fundamental roles they have in food intake regulation.  The PVN, ARC and 
DMH relate to homeostatic feeding, their separate roles work together to form a 
coordinated feeding response. In line with that, the PVN is a key sit of integration 
from signals received from the CNS and the ARC, and it serves as a key source of 
neural and neurohormonal input to the pituitary (116). Injections of orexigenic 
hormone ghrelin, or conversely the anorexigenic hormone leptin into the PVN 
alters appetite accordingly (117, 118). The ARC also integrates information 
received from circulating hormones due to its weak BBB (119), information 
projects to relevant brain sites including the PVN (50). The ARC is the primary site 
for orexingenic neurons synthesising NPY and AgRP (37), and it projects to the 
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DMH (120). It should be particularly emphasised that the lack of increase in the 
nucleus accumbens shell defines a likely neuroanatomical component of the 
reward system whose diminished responsiveness to naltrexone might play a 
significant role to the diminished anorexigenic effect of this opioid receptor 
ligand in aged animals. It is very much in line with data showing that opioid 
receptor ligands increase food consumption particularly well when injected 
directly in the shell subdivision of the accumbens complex (121). 
The activation of the LH in the old mice is interesting due to the combined role it 
plays in food intake regulation and the sleep-wake cycle. The LH is a key area for 
expression of orexin neurons. Opioid systems within the LH regulate feeding via 
orexin neurons. They cause orexigenic effects and increased arousal (122, 123). 
Studies have shown that orexin injected directly into the LH, increases ethanol 
drinking in rats (124). Other studies show that downregulation of opioid 
receptors within the LH decrease food intake via inhibition of orexin neurons. 
(60). Injecting naltrexone directly into the LH significantly reduces deprivation-
induced feeding in mice (125). The LH and orexin neurons also play a significant 
role in sleep regulation involved in the sleep wake cycle. This is important as 
aging is not only associated with appetite disturbances, as sleep problems are 
common among the elderly (126). Orexins are found in high levels during the 
waking period and low levels during sleep (127). Orexin receptor knockout mice 
show a sleep disturbance behaviour known as narcolepsy in humans (128). In 
fact, orexin deficient narcolepsy is primarily defined by a difficulty to stay awake 
during the day (129). Sleep in the elderly is characterised by an earlier wake time 
compared to younger adults. There is also a tendency for older people to be 
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disrupted during sleep and therefore is aging is associated with a decrease in the 
duration and the consolidation of the sleep (127). As the older old mice in this 
current study showed activity in the LH, it would be of interest to look into this 
area further and assess the mechanisms that contribute to dysregulated sleep 
and appetite processes on neurochemistry and transcriptional activity at an 
advanced age.  
As an additional pilot study, I also wished to examine by using the rat model 
whether adult animals that are less advanced in age show a differential 
responsiveness to naltrexone. I therefore compared two cohorts – one whose 
age was 2 months at the beginning of the experimental trials (thus, they can be 
considered as entering the adult phase of their lifespan), and the other that was 
18 months, thus the animals that still do not show the full repertoire and 
behavioural and physiological changes associated with an old age. I found that 
the same 0.3mg/kg of b. wt. dose of naltrexone was necessary to decrease 
deprivation-induced chow intake and episodic sucrose intake in rats at both ages. 
Surprisingly, I did not detect a naltrexone-induced reduction in saccharin 
consumption in any of the age cohorts. It should be noted, however, that our 
rats seem to consume quite low quantities of saccharin compared to sucrose, 
which suggests that they may be non-preferrers of saccharin. That rats can differ 
greatly in their inherent preference for saccharin has been well documented in 
previous studies, in which preference for this tastant could be achieved even by 
selective breeding for this phenotype (130, 131). Consequently, intake of a non-
preferred saccharin may not be sensitive to opioid antagonism.  
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In order to provide additional evidence that there is no difference in sensitivity 
between the varying ages of adult rats in my project, aside from testing these 
animals in naltrexone injection studies, I also assessed whether they would differ 
in sensitivity to an opioid receptor agonist, butorphanol. older group of rats.  The 
results showed an increase in chow intake available ad libitum in both age 
groups.  Notably, Gosnell et al, who also used burtorphanol in found that the two 
older groups of rats aged 22 and 28 months old were much less responsive to the 
opioid agonist than their younger counterparts (93). It indicates that 18 months 
of age is not yet the threshold age in rats to display different sensitivity to 








The findings indicate that old (22-month old) mice exhibit diminished 
responsiveness to anorexigenic properties of naltrexone in feeding paradigms 
that involve eating for energy (deprivation-induced intake of “bland” chow) and 
eating for reward (consumption of low-/non-calorie solutions containing sucrose 
and saccharin). The c-Fos immunoreactivity analysis indicates that unlike in adult 
mice at a younger age, in old animals, naltrexone fails to activate the nucleus 
accumbens shell, the ventromedial and hypothalamic nuclei, and it activates the 
lateral hypothalamus. These c-Fos data provide an insight into neural 
responsiveness changes that might underscore a differential feeding regulatory 
outcomes seen after naltrexone administration.  Finally, naltrexone is similarly 
effective in reducing food intake in 2-month old rats as in the 18-month old 
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